datavisyn specializes in creating unique data visualization tools and interactive analytic platforms. Our software applications are designed to integrate and interpret complex biomedical or chemical datasets to streamline analytical workflows. Backbone of our products is a unique curated database of public data from 80+ biological, compound, drug, and disease-specific repositories. Targeted at researchers and data scientists in R&D, clinical development, and CMC, these apps unlock visual clarity in scientific data, driving faster decision-making. Our Products: 𝗢𝗿𝗱𝗶𝗻𝗼 | Enabling Discovery: An interactive visual data analysis tool to explore, filter, rank, and visualize large, integrated biomedical datasets. 𝗔𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲 | Deep Dive into Target Insights: A suite of specialized apps for scientific discovery, disease understanding, and biomarker development. 𝘃𝗶𝘀𝘆𝗻𝗞𝗻𝗼𝘄𝗹𝗲𝗱𝗴𝗲𝗯𝗮𝘀𝗲 | Data Drives Drug Discovery: A curated database of public data from over 80 biological, compound, drug, and disease-specific repositories. It serves as the backbone for our Ordino and Aevidence applications. In-house experimental data and other sources can be easily integrated on a custom basis. In addition to our core products, datavisyn provides expert services, including the development of new visual analytics and reporting solutions. Founded in 2016 by four leading visual data scientists with roots in top research institutions, including JKU Linz, the University of Utah, the University of Graz, and Harvard University, datavisyn is headquartered in Linz, Austria.
External link for datavisyn
Gewerbepark Urfahr 8
Linz, Upper Austria 4040, AT
datavisyn reposted this
𝗕𝗶𝗼-𝗜𝗧 𝗪𝗼𝗿𝗹𝗱 𝗘𝘅𝗽𝗼 is lively today! ✈️📊 We are set up and waiting for you at Booth #𝟱𝟭𝟲. Come see a quick live demo of how we harmonize curated data (visynKB), target prioritization (Ordino), and discovery apps (Aevidence) into one powerful ecosystem. We’d love to show you how the visynPlatform is making multi-omic data completely interactive and AI-agent ready. Let’s chat about streamlining your research workflows! #BioITWorld #DrugDiscovery #ScientificComputing
𝗕𝗶𝗼-𝗜𝗧 𝗪𝗼𝗿𝗹𝗱 𝗘𝘅𝗽𝗼 is lively today! ✈️📊 We are set up and waiting for you at Booth #𝟱𝟭𝟲. Come see a quick live demo of how we harmonize curated data (visynKB), target prioritization (Ordino), and discovery apps (Aevidence) into one powerful ecosystem. We’d love to show you how the visynPlatform is making multi-omic data completely interactive and AI-agent ready. Let’s chat about streamlining your research workflows! #BioITWorld #DrugDiscovery #ScientificComputing
𝗖𝗼𝘂𝗻𝘁𝗱𝗼𝘄𝗻 𝘁𝗼 𝗕𝗶𝗼-𝗜𝗧 𝗪𝗼𝗿𝗹𝗱 𝗘𝘅𝗽𝗼 𝗶𝘀 𝗼𝗻!⏳ The datavisyn team is landing in Boston next week. Visit Dominic, Matthew, and Susanne at 𝗕𝗼𝗼𝘁𝗵 #𝟱𝟭𝟲 to see our latest platform updates in action. We’ll be showcasing how the 𝘃𝗶𝘀𝘆𝗻 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺 is helping scientists turn complex drug discovery data into actionable insights. Let’s discuss how we can simplify your research workflows. Stop by for a demo, a chat, or just to say hello! 🧬🚀 #BioITExpo #Bioinformatics #visyn #SoftwareDesign #DataScience #Biotech #DrugDiscovery #DataVis #BostonTech
𝗖𝗼𝗻𝗳𝗲𝗿𝗲𝗻𝗰𝗲 𝘀𝗲𝗮𝘀𝗼𝗻 𝗶𝘀 𝗼𝗳𝗳𝗶𝗰𝗶𝗮𝗹𝗹𝘆 𝗵𝗲𝗿𝗲!🧬💻 Susanne, Dominic and Matthew are currently busy packing their bags for BioIT World in Boston! ✈️🇺🇸 What are we bringing to the table this year? Beyond our usual enthusiasm, we’re showcasing the latest evolution of the 𝘃𝗶𝘀𝘆𝗻 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺: 🚀 𝗔𝗴𝗲𝗻𝘁-𝗥𝗲𝗮𝗱𝘆 𝗔𝗽𝗽𝘀:We’re making our tools smarter and more accessible for the next wave of AI-driven research. 🧪 𝗡𝗲𝘄 𝗦𝗽𝗲𝗰𝗶𝗮𝗹𝗶𝘀𝘁 𝗔𝗽𝗽𝘀:Fresh developments across our analytical layers to turn messy R&D data into clear roadmaps. 📊 𝗦𝗲𝗮𝗺𝗹𝗲𝘀𝘀 𝗪𝗼𝗿𝗸𝗳𝗹𝗼𝘄𝘀: High-speed interactivity that keeps up with your brain, not your loading bar. If you’re heading to the 𝗕𝗶𝗼𝗜𝗧 𝗪𝗼𝗿𝗹𝗱 𝗘𝘅𝗽𝗼 (May 19-21), come say hi to the team! We’d love to show you what we've been building and discuss how we can help automate your scientific discovery. Ready to unlock your data’s full potential? See you in Boston! 🦀 #BioITWorld #DrugDiscovery #Bioinformatics #visyn #ScientificComputing #AgentReady #AIinScience
𝗙𝗮𝗰𝗲-𝘁𝗼-𝗙𝗮𝗰𝗲 𝘄𝗶𝘁𝗵 𝗜𝗻𝗻𝗼𝘃𝗮𝘁𝗶𝗼𝗻: 𝗔𝗜 𝗛𝗮𝗰𝗸𝗮𝘁𝗵𝗼𝗻 𝗥𝗲𝗰𝗮𝗽🚀🔬 At datavisyn, we believe the best solutions are built side by side with our partners. Our team Michael, Thomas, and Klaus —recently headed out for a dedicated Hackathon workshop with the team at Bayer. 🤝 𝗔 𝗟𝗼𝗻𝗴𝘀𝘁𝗮𝗻𝗱𝗶𝗻𝗴 𝗣𝗮𝗿𝘁𝗻𝗲𝗿𝘀𝗵𝗶𝗽 Bayer was one of our very first clients, and 𝗔𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲 was originally co-developed with them. These on-site workshops are vital to maintaining the sustainable, long-term relationships that drive real progress in life sciences. 💡 𝗔𝗜 𝗶𝘀 𝗮 𝗗𝗮𝘁𝗮 𝗦𝘁𝗼𝗿𝘆 This session focused on integrating the latest 𝗔𝗜 𝘁𝗲𝗰𝗵𝗻𝗼𝗹𝗼𝗴𝗶𝗲𝘀 into the 𝗔𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲 platform. As the industry shifts toward automated discovery, we are ensuring the "foundation work" is solid: • Integrating AI layers into consistent data infrastructures. • Refining workflows directly with the scientists who use them. Organizations like Bayer are leading the way by building these robust foundations. The question for the rest of the industry remains: 𝗛𝗼𝘄 𝗳𝗮𝘀𝘁 𝗰𝗮𝗻 𝘁𝗵𝗲𝘆 𝗳𝗼𝗹𝗹𝗼𝘄? #datavisyn #Bayer #AI #DrugDiscovery #DataInfrastructure #Innovation #Partnership #Aevidence #LifeSciences #Teamwork #DataScience
🍕 𝗣𝗶𝘇𝘇𝗮, 𝗣𝗲𝗿𝘀𝗽𝗲𝗰𝘁𝗶𝘃𝗲𝘀, 𝗮𝗻𝗱 𝗗𝗮𝘁𝗮𝗨𝗫 It was a true pleasure to host the recent 𝗗𝗮𝘁𝗮𝗨𝗫 𝗠𝗲𝗲𝘁𝘂𝗽 as our first official event at our new datavisyn office! We welcomed a full house to dive into a topic close to our hearts: 𝗗𝗮𝘁𝗮𝗨𝗫. In a domain as complex as ours, how we design for data is just as critical as the data itself. The evening was packed with deep dives and great conversations: Mandy Keck'𝘀 𝗧𝗮𝗹𝗸: "Data tells a story, but how we frame it changes the outcome." Mandy explored the crucial role of 𝗯𝗶𝗮𝘀 𝗮𝗻𝗱 𝗳𝗿𝗮𝗺𝗶𝗻𝗴 in data design—a vital reminder that we aren’t just building tools; we are shaping the perspectives of decision-makers. Daniela Moitzi'𝘀 𝗧𝗮𝗹𝗸: I focused on why interactive analysis in complex domains isn't just about display; it’s about 𝗲𝗻𝗮𝗯𝗹𝗶𝗻𝗴 𝗱𝗶𝘀𝗰𝗼𝘃𝗲𝗿𝘆 while allowing users to maintain focus in high-pressure environments. It was inspiring to see our new office kitchen come alive with such high-level discussions on UX and design. As one visitor perfectly put it: "Data tells stories, but how we tell them makes the difference. It shows how much responsibility lies within the data." We couldn't agree more. Whether in bioinformatics or business, tools must make data tangible and explainable. A massive thank you to the organizer Thomas Grill, and everyone who joined us and shared their experiences. #datavisyn #DataUX #UXDesign #DataVisualization #MeetupLinz #Innovation #LifeAtDatavisyn #UserExperience #Bioinformatics
We couldn’t agree more with the insights shared by Lavinia Woodward regarding her comments from the 2026 Pistoia Alliance conference. The industry often talks about generative chemistry and structure prediction, but the real "unglamorous" challenge remains: handling pharma's unstructured, high-volume data workflows. As the post rightly states: "𝗧𝗵𝗲 𝗔𝗜 𝗹𝗮𝘆𝗲𝗿 𝗶𝘀 𝘄𝗵𝗮𝘁 𝘁𝗵𝗲 𝗮𝘂𝗱𝗶𝗲𝗻𝗰𝗲 𝘀𝗲𝗲𝘀. 𝗧𝗵𝗲 𝗱𝗮𝘁𝗮 𝗳𝗼𝘂𝗻𝗱𝗮𝘁𝗶𝗼𝗻𝘀 𝗮𝗿𝗲 𝘄𝗵𝗮𝘁 𝗺𝗮𝗱𝗲 𝗶𝘁 𝗽𝗼𝘀𝘀𝗶𝗯𝗹𝗲." At datavisyn, we have built the solution to this exact problem. We bridge the gap between complex data and actionable insights with our 𝗔𝗜-𝗮𝗴𝗲𝗻𝘁-𝗿𝗲𝗮𝗱𝘆 𝘃𝗶𝘀𝘆𝗻𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺. We don’t just provide an AI layer; we provide the scalable infrastructure that makes multi-agent discovery possible: ✅ 𝘃𝗶𝘀𝘆𝗻𝗞𝗻𝗼𝘄𝗹𝗲𝗱𝗴𝗲𝗯𝗮𝘀𝗲: The "single source of truth." We harmonize 80+ public repositories with your proprietary in-house data to ensure your data foundation is findable, parseable, and semantically consistent. ✅ 𝗢𝗿𝗱𝗶𝗻𝗼: A powerful visual interface to rank and prioritize targets and biomarkers across integrated datasets. ✅ 𝗔𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲: A specialized suite of interactive applications to evaluate and organize the scientific evidence behind your therapeutic concepts. Ready to turn your data infrastructure into a competitive advantage? Explore the visynPlatform. Contact us for a demo and free trial! #DataScience #PharmaAI #BioIT #DrugDiscovery #DataInfrastructure #datavisyn #VisualAnalytics #PistoiaAlliance
The Pistoia Alliance's 2026 Data Science Team of the Year shortlist, announced at last week's London conference, is worth reading carefully for what it signals about where the industry is directing its AI investment - and, more tellingly, what it no longer treats as prize-worthy. Three finalists: ▪ Roche (winner): pan-cancer digital twins for clinical prediction, presented by Raul Rodriguez-Esteban ▪ AstraZeneca: the CMC Data Hub, which reportedly cut CDMO data transfer time from four weeks to under 24 hours, presented by Sophie Bailes ▪ Bayer: the PRINCE project, a multi-agent system synthesising preclinical data across the 159 documents and 16,000 pages that accompany each drug submission, led by Annika Kreuchwig and presented by Dr. Carlos Henrique Vieira e Vieira on behalf of the team Three teams. Three very different parts of the value chain: clinical prediction, manufacturing data exchange, preclinical documentation. One shared characteristic. None is a drug discovery story. None is a target identification model, a generative chemistry platform, or a structure prediction tool. All three apply AI to the unglamorous problem of handling pharma's unstructured, high-volume, time-consuming data and documentation workflows. That is a notable shift from the industry's AI narrative of even two years ago. What the pattern suggests: The centre of gravity has moved. The industry is recognising applications that reduce friction in existing evidence-generation workflows rather than those promising to replace scientific judgment. The work closest to production and furthest from speculation was rewarded. The shortlist is quietly agentic. Two of the three finalists use multi-agent architectures. Roche's digital twins use reinforcement learning to reason over noisy, out-of-sample data. A year ago, agentic AI was a demo. This year, it is the winning deployment pattern at three of the most sophisticated R&D organisations in the sector. And the under-discussed point: all three winners are data-infrastructure stories dressed as AI stories. Digital twins require multi-modal, longitudinal, clinically annotated patient data. CMC transfer optimisation requires ontologies and shared vocabularies across a sponsor and its CDMOs. Multi-agent preclinical synthesis requires every one of those 16,000 pages to be findable, parseable, and semantically consistent. The AI layer is what the audience sees. The data foundations are what made it possible. The interesting pharma AI work in 2026 is not about whether the models are capable. It is about whether the data estate, the ontology layer, and the governance scaffolding are ready to let capable models do defensible work. Read that way, the shortlist is less a trophy list than a diagnostic. These organisations are doing the foundation work. The question for the rest of the industry is how fast they can follow. More to come on the rest of the conference shortly. #PistoiaAlliance #datascience #pharmaAI
🏁 𝗙𝗿𝗼𝗺 𝟴𝗸 𝘁𝗼 𝟮𝟱𝗸: 𝗙𝗶𝗿𝘀𝘁 𝗖𝗹𝗮𝘀𝘀 𝗧𝗲𝗮𝗺 𝗦𝗽𝗶𝗿𝗶𝘁 𝗮𝘁 𝗟𝗶𝗻𝘇 𝗠𝗮𝗿𝗮𝘁𝗵𝗼𝗻 🏃♂️🍻 If you want to know what "team spirit" looks like at datavisyn, look no further than the results of this weekend’s Linz Marathon. It wasn’t just about the miles; it was about showing up when things didn’t go according to plan. 🚀 𝗧𝗵𝗲 𝗦𝗽𝗲𝗲𝗱𝘀𝘁𝗲𝗿𝘀 A huge shoutout to our Quarter Marathon crew—Holger, Matthew, and Usama—who set the pace and showed us how it’s done! Our marathon pro Thomas crushed a 2:47 finish—beating his first marathon time by exactly one hour! He left everything on the track, ending the race horizontally from exhaustion (the same effort he puts in daily for our customers, as he jokingly claims). 🥨𝗧𝗵𝗲 "𝗜𝗺𝗽𝗿𝗼𝘃𝗶𝘀𝗲𝗱" 𝗥𝗲𝗹𝗮𝘆 The real drama (and the real heart) of the day happened with our relay team. After Amin unfortunately got injured just the night before, we were one runner short. What happened next defines our culture: - Viktor stepped up in a big way. Despite his longest previous run being only 8 km, he took on a staggering 𝟮𝟱 𝗸𝗺 to cover the gap. - Matt jumped back in after his own race to provide the emotional support needed to get through those extra miles. - Franz and Oltion C. held down their sections, with Oli bringing it home for the final stretch. 🍻 𝗟𝗮𝘀𝘁 𝗣𝗹𝗮𝗰𝗲, 𝗙𝗶𝗿𝘀𝘁 𝗖𝗹𝗮𝘀𝘀 Because of the last-minute changes and the Herculean effort required, the datavisyn relay team finished... 𝗱𝗲𝗮𝗱 𝗹𝗮𝘀𝘁. 🐢 But at the end of the day, we didn't just finish a marathon; we proved that whether it's a code sprint or a literal sprint, we’ve always got each other's backs (and a cold drink waiting at the finish line). 𝗖𝗼𝗻𝗴𝗿𝗮𝘁𝘀 𝘁𝗼 𝘁𝗵𝗲 𝘄𝗵𝗼𝗹𝗲 𝘁𝗲𝗮𝗺!🚀 #datavisyn #LinzMarathon #TeamSpirit #WorkLifeBalance #MarathonTraining #NeverGiveUp #LifeAtDatavisyn #RelayRace #Linz #MarathonStories
We are pleased to welcome Robert F. Siegmund, PhD MBA to the datavisyn team as our new Business Development Partner for the Swiss market! 🇨🇭🚀 Based in Switzerland, he will be leveraging his deep R&D network to connect our visual data science platforms, 𝗢𝗿𝗱𝗶𝗻𝗼 and 𝗔𝗲𝘃𝗶𝗱𝗲𝗻𝗰𝗲, with leading biopharma and biotech innovators. His expertise ensures that we don't just provide tools, but true solutions for target prioritization and evidence integration. Welcome aboard, Robert! We look forward to driving the future of traceable, data-driven discovery together. https://lnkd.in/gzp492qU https://lnkd.in/gYS7iB8j #datavisyn #DrugDiscovery #SwissBiotech #BioPharma #DataVisualization #BusinessDevelopment #Innovation
I am pleased to announce my collaboration with datavisyn, a leading visual data science company based in my hometown of Linz, Austria, focused on enabling discovery in biopharmaceutical R&D. In many R&D organizations, critical decisions are still slowed down by fragmented data, disconnected evidence sources, and workflows that are difficult to reproduce or explain. datavisyn addresses this challenge with a suite of interactive platforms—Ordino and Aevidence—that bring together complex biological and chemical data and curated scientific evidence into a single, intuitive workflow. This enables research teams to explore, prioritize, and validate targets in a more integrated, transparent, and ultimately faster way. Backbone of our products is a unique curated database of public data from 80+ biological, compound, drug, and disease-specific repositories. What I find particularly compelling is the emphasis on traceability and usability: analyses can be reproduced, shared, and revisited, moving beyond fragmented workflows and disconnected tools, and towards decisions that are both data-driven and explainable. In my role as Business Development Partner at datavisyn, I bring a combination of scientific, strategic, and analytical experience, from a PhD in molecular biology and early R&D work to many years in insights and strategy in pharma, complemented by a strong focus on data science, analytics, and data visualization. I have always seen data visualization as both an art and a science—critical for turning complexity into clarity. My focus will be on supporting biopharma and biotech companies in Switzerland, leveraging my network across R&D to connect datavisyn’s capabilities to concrete, high-impact use cases in discovery and translational research. If you are currently working through challenges around target prioritization, evidence integration, or decision traceability in R&D, I would be glad to connect and arrange a short discussion or demonstration.
datavisyn reposted this
I am pleased to announce my collaboration with datavisyn, a leading visual data science company based in my hometown of Linz, Austria, focused on enabling discovery in biopharmaceutical R&D. In many R&D organizations, critical decisions are still slowed down by fragmented data, disconnected evidence sources, and workflows that are difficult to reproduce or explain. datavisyn addresses this challenge with a suite of interactive platforms—Ordino and Aevidence—that bring together complex biological and chemical data and curated scientific evidence into a single, intuitive workflow. This enables research teams to explore, prioritize, and validate targets in a more integrated, transparent, and ultimately faster way. Backbone of our products is a unique curated database of public data from 80+ biological, compound, drug, and disease-specific repositories. What I find particularly compelling is the emphasis on traceability and usability: analyses can be reproduced, shared, and revisited, moving beyond fragmented workflows and disconnected tools, and towards decisions that are both data-driven and explainable. In my role as Business Development Partner at datavisyn, I bring a combination of scientific, strategic, and analytical experience, from a PhD in molecular biology and early R&D work to many years in insights and strategy in pharma, complemented by a strong focus on data science, analytics, and data visualization. I have always seen data visualization as both an art and a science—critical for turning complexity into clarity. My focus will be on supporting biopharma and biotech companies in Switzerland, leveraging my network across R&D to connect datavisyn’s capabilities to concrete, high-impact use cases in discovery and translational research. If you are currently working through challenges around target prioritization, evidence integration, or decision traceability in R&D, I would be glad to connect and arrange a short discussion or demonstration.